Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Drug Des Devel Ther. 2024 Jun 26;18:2571-2591. doi: 10.2147/DDDT.S465238. eCollection 2024.
Activating mutations in epidermal growth factor receptor (EGFR) have been identified as key predictive biomarkers for the customized treatment with EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC), aiding in improving patient response rates and survival. However, resistance challenges the efficacy of these treatments, with limited understanding of post-resistance therapeutic strategies. A deep understanding of the biology and resistance mechanisms of EGFR-mutant NSCLC is crucial for developing new treatment approaches. This study, through bibliometric analysis, summarizes the trends in research on resistance to EGFR-TKIs.
Research papers on NSCLC with EGFR inhibitor resistance were collected from the Web of Science Core Collection (WoSCC). The analysis utilized bibliometric tools like CiteSpace, VOSviewer, and other platforms for comprehensive analysis and visualization of the outcomes.
The WoSCC database contains a total of 5866 documents on resistance to EGFR-TKIs treatment, including 4727 articles (93.48%) and 1139 reviews (6.52%), spanning 81 countries and regions, 4792 institutions, with the involvement of 23,594 authors. Since 2016, there has been a significant increase in publications in this field. China has the highest publication output, while the United States has the highest citation count for papers. Harvard University leads in terms of the number of publications. Among the top ten journals with the highest output, Clinical Cancer Research has the highest impact factor at 11.5, with 90% of the journals classified in Q1 or Q2. Rafael Rosell is one of the most influential authors in this field, ranking second in publication volume and fourth in citation count. Research on EGFR-TKIs resistance mainly focuses on genetic testing, resistance mechanisms, and post-resistance treatment strategies.
This study provides researchers with a reliable basis and guidance for finding authoritative references, understanding research trends, and exploring potential directions.
表皮生长因子受体（EGFR）的激活突变已被确定为非小细胞肺癌（NSCLC）中使用 EGFR 酪氨酸激酶抑制剂（TKI）进行个体化治疗的关键预测生物标志物，有助于提高患者的反应率和生存率。然而，耐药性挑战了这些治疗方法的疗效，对耐药后治疗策略的了解有限。深入了解 EGFR 突变型 NSCLC 的生物学和耐药机制对于开发新的治疗方法至关重要。本研究通过文献计量分析总结了 EGFR-TKI 耐药性研究的趋势。
从 Web of Science 核心合集（WoSCC）中收集了关于 NSCLC 对 EGFR 抑制剂耐药的研究论文。该分析利用了 CiteSpace、VOSviewer 等工具，对结果进行了全面分析和可视化。
WoSCC 数据库中共有 5866 篇关于 EGFR-TKI 耐药治疗的文献，包括 4727 篇文章（93.48%）和 1139 篇综述（6.52%），涵盖 81 个国家和地区、4792 个机构，涉及 23594 名作者。自 2016 年以来，该领域的出版物数量显著增加。中国的发表量最高，美国的论文被引次数最高。哈佛大学在发文量方面排名第一。在发文量最高的十大期刊中，Clinical Cancer Research 的影响因子最高，为 11.5，90%的期刊被归类为 Q1 或 Q2。Rafael Rosell 是该领域最有影响力的作者之一，在发文量排名第二，被引次数排名第四。EGFR-TKI 耐药性的研究主要集中在基因检测、耐药机制和耐药后治疗策略上。
本研究为研究人员提供了可靠的依据和指导，帮助他们找到权威参考文献、了解研究趋势和探索潜在方向。
